AUS
NZ
UK
CA
USA
IND
Healt
Can Pro Medicus (ASX:PME) Bounce Back? A Closer Look at the Radiology Software Leader
April 30, 2025 04:30 PM AEST| By Team Kalkine MediaHighlights,Pro Medicus' core tech supports entire radiology process,Visage platform enables remote, real-time diagnostics,Strong fundamentals despite recent share price dip,After a strong multi-year run, shares of,Pro Medicus Ltd (ASX:PME),have dippe...
Zelira Therapeutics Enhances Capital Strength and Advances Clinical Pipeline
April 29, 2025 05:59 PM AEST| By Team Kalkine MediaHighlights,Zelira secures over $1 million through R&D tax refund,Establishes new equity funding avenue via ATM facility,Completes debt-to-equity conversion, enhancing balance sheet,Zelira Therapeutics (ASX:ZLD) has taken several strategic steps to en...
4DMedical (ASX:4DX) Delivers Strong Revenue Growth and Strategic Advances in FY2025
April 29, 2025 05:27 PM AEST| By Team Kalkine MediaHighlights,4DMedical revenue surges 103% year-to-date,Strategic U.S. and Australian partnerships strengthen growth,Regulatory milestones advance global market expansion,4DMedical (ASX:4DX) has reported an impressive 103% increase in operating revenue...
InteliCare (ASX:ICR) Expands AI Reach with mecwacare Collaboration at Trescowthick Centre
April 29, 2025 05:15 PM AEST| By Team Kalkine MediaHighlights,InteliCare (ICR) partners with mecwacare for AI platform trial.,$212,000 initial agreement signed for deployment at Trescowthick Centre.,Potential expansion across mecwacare’s facilities based on trial success.,InteliCare Holdings Ltd (ASX...
Paradigm Biopharmaceuticals (ASX:PAR) Sets the Stage for Next Growth Chapter with Phase 3 Trial Launch
April 29, 2025 05:11 PM AEST| By Team Kalkine MediaHighlights,Paradigm Biopharmaceuticals launches Phase 3 trial for knee osteoarthritis treatment,Strong financial position with $24.56 million cash balance reported,Shareholder loyalty initiatives introduce potential for over $110 million in future ca...
CSL and Pro Medicus: Two ASX Healthcare Giants Gaining Attention in 2025
April 29, 2025 02:26 PM AEST| By Team Kalkine MediaHighlights,CSL (CSL) shows resilience with growing dividends despite share price pullback.,Pro Medicus (PME) gains strong momentum, soaring from 52-week lows.,Healthcare sector innovations drive long-term investor interest.,The Australian healthcare...
Algorae Pharmaceuticals Boosts Drug Pipeline and AI Capabilities with AlgoraeOS 2.0
April 29, 2025 01:33 PM AEST| By Team Kalkine MediaHighlights,AlgoraeOS identifies 24 new drug targets in major oncology areas,AI-116 shows potential dementia treatment superiority,Strong cash position supports expanding R&D efforts,Algorae Pharmaceuticals (ASX:1AI) is making strong strides in drug d...
Sudden Exit: Telix Pharmaceuticals Board Member Anne Whitaker Steps Down
April 29, 2025 10:43 AM AEST| By Team Kalkine MediaHighlights,Anne Whitaker steps down from,Telix,board after a short tenure.,Resignation,driven,by personal and family circumstances.,Telix,Pharmaceuticals expresses support for Whitaker’s future endeavors.,Telix Pharmaceuticals (ASX:TLX) has announced...
ResMed Delivers Solid Performance Amidst Ongoing Market Leadership
April 28, 2025 09:31 PM AEST| By Team Kalkine MediaHighlights:,ResMed's third-quarter fiscal result showed steady growth despite typical seasonal challenges and currency fluctuations.,The company continues to expand its presence in the global obstructive sleep apnea market through innovative smart de...
ASX Healthcare Leader: ResMed’s Steady Growth in the OSA Market
April 28, 2025 08:53 PM AEST| By Team Kalkine MediaHighlights:,ResMed remains a dominant player in the global obstructive sleep apnea market, alongside Philips, with a strong presence in over 140 countries.,Third-quarter fiscal results showed positive growth despite typical seasonal challenges, with...
FDA Rejects Telix Pharmaceuticals' Glioma Imaging Agent Submission
April 28, 2025 05:36 PM AEST| By Team Kalkine MediaHighlights:,Telix Pharmaceuticals faces a setback as the FDA declines approval for its glioma imaging agent.,The regulatory body requests additional clinical evidence for the new drug application.,The decision does not affect Telix's financial outloo...
Cochlear Ltd (ASX:COH) Share Price Analysis in 2025
April 28, 2025 05:21 PM AEST| By Team Kalkine MediaHighlights:,Cochlear Ltd’s share price has decreased by approximately 7.5% since the start of 2025.,The company continues to lead in the global hearing device market with a broad international presence.,Currently, Cochlear Ltd shares are trading at a...
Radiopharm Theranostics (ASX:RAD) Advances Brain Metastasis Imaging with Promising Phase 2b Trial
April 28, 2025 03:45 PM AEST| By Team Kalkine MediaHighlights,Radiopharm Theranostics initiates Phase 2b trial for brain metastasis imaging.,18F-RAD101 targets fatty acid synthase for enhanced diagnostic precision.,Topline results expected in the second half of 2025.,Radiopharm Theranostics (ASX:RAD)...
EMVision dispatches its bedside brain scanning device to Mayo Clinic for evaluation at a second testing location.
April 28, 2025 01:31 PM AEST| By Team Kalkine MediaHighlights:,EMVision (ASX:EMV) enhances emergency care with bedside brain imaging technology.,Portable brain scanner aims to support first responders at incident sites.,Testing initiatives underway in leading US and Australian medical institutions.,T...
TrivarX Approved for US Trial to Use Heart Rate in Identifying Depression in Veterans
April 28, 2025 01:30 PM AEST| By Team Kalkine MediaHighlights:,TrivarX (ASX:TRI) initiates a trial using heart rate data to detect depression in US veterans.,The trial proceeds through collaboration with the Greater Los Angeles Veterans Research and Education Foundation and the US Department of Veter...
Pharmaceutical Sector: Telix Pharmaceuticals Addresses FDA Data Requirements for Imaging Agent
April 28, 2025 01:30 PM AEST| By Team Kalkine MediaHighlights:,Telix Pharmaceuticals faced an FDA request for additional data on TLX101-CDx.,TLX101-CDx holds Orphan Drug and Fast Track designations for glioma diagnosis.,Telix is advancing its clinical programs to meet regulatory requirements.,The pha...
ResMed (ASX:RMD): Why Healthcare Shares Continue to Win Investor Confidence
April 28, 2025 12:49 PM AEST| By Team Kalkine MediaHighlights,ResMed (RMD),operates,a global healthcare business with expanding digital health capabilities.,Healthcare sector’s 'sticky' revenue offers resilience during economic downturns.,Growth and sustainability trends are boosting healthcare inves...
Setback for Telix Pharmaceuticals (ASX:TLX) as FDA Requests Additional Data for Brain Cancer Imaging Agent
April 28, 2025 12:48 PM AEST| By Team Kalkine MediaHighlights,FDA issues complete response letter for TLX101-CDx application,No safety concerns raised for investigational brain cancer imaging agent,Telix,Pharmaceuticals to pursue,additional,clinical strategies for resubmission,Telix Pharmaceuticals (...
FDA Setback Hits Telix Pharmaceuticals' Imaging Agent Ambitions
April 28, 2025 12:44 PM AEST| By Team Kalkine MediaHighlights,Telix,Pharmaceuticals faces FDA roadblock for glioma imaging agent,Additional,clinical data,required,for TLX101-CDx approval,Company's financial guidance,remains,unaffected,Telix Pharmaceuticals (ASX:TLX) encountered a major hurdle after t...
Recce Pharmaceuticals Strengthens Biodefense Strategy with New US Army Research Agreement
April 28, 2025 11:55 AM AEST| By Team Kalkine MediaHighlights,Recce Pharmaceuticals advances partnership with US Army.,R327 to be tested against deadly pathogens under high biocontainment.,Collaboration boosts efforts to combat antimicrobial resistance.,Recce Pharmaceuticals (ASX:RCE) has taken a sig...
Advertise your brand on Kalkine Media